HLHyejin Lee

Hyejin Lee

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hyejin Lee has a total of 3 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Bone marrow organoid-based platforms overcoming barriers to predictive modeling of hematopoietic stem cell engraftment

    by Chaeyoun Lee, Yoonseo Choi, Hyejin Lee, Byung-Chul Lee

    Hematopoietic stem cell transplantation (HSCT) has long served as an unparalleled therapeutic option for numerous hematologic malignancies and genetic disorders. However, the efficacy of HSCT is often limited by suboptimal homing of transplanted stem cells to the bone marrow (BM) niche and insufficient long-term engraftment. Despite the need for effective methods to predict clinical outcomes, a suitable model system remains lacking. In this review, we first examine the biological factors that govern hematopoietic stem cell (HSC) homing and niche interactions, including key chemokine–receptor axes (such as CXCR4–CXCL12) and regulatory molecules that facilitate long-term HSC quiescence and repopulation. We then explore how CRISPR-based gene editing technologies are leveraged to modify HSCs for improved clinical outcomes, while addressing the challenges of DNA damage responses and off-target effects associated with editing. Most importantly, we highlight emerging BM organoid (BMO) systems as next-generation 3-dimensional culture models that recapitulate the human BM microenvironment. BMOs represent a promising platform for preclinical testing of gene-edited HSCs and for investigating human-specific HSC–niche interactions beyond animal models. By integrating gene-edited HSCs with organoid models, researchers can more accurately evaluate HSC homing and engraftment in a precisely mimicked, human-like environment. We also emphasize the potential of combining gene editing with BMO technologies to advance personalized HSCT and pave the way for safer, more effective transplantation procedures. Despite their promise, current BMOs exhibit limitations such as incomplete tissue recapitulation, lack of vascularization, batch variability, and limited long-term stability. Addressing all these challenges will be essential for increasing their physiological relevance and translational potential.